Complications of uncontrolled use of topical and systemic glucocorticosteroids: clinical cases
- Авторлар: Nemchaninova О.В.1, Reshetnikova T.B.1, Pozdnyakova O.N.1, German R.V.1
-
Мекемелер:
- Novosibirsk State Medical University
- Шығарылым: Том 30, № 8 (2023)
- Беттер: 134-138
- Бөлім: Clinical case
- URL: https://journals.eco-vector.com/2073-4034/article/view/623173
- DOI: https://doi.org/10.18565/pharmateca.2023.8.134-138
- ID: 623173
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Background. Glucocorticosteroids (GCS) have been successfully used since the discovery of hydrocortisone and remain the most commonly used group of drugs included in the treatment plans of patients with skin pathology. This is attributable to their ability to effectively influence both the pathogenetic mechanisms and the symptoms of skin diseases. For the effective and safe use of topical and systemic corticosteroids, it is necessary to comply with the indications and rules for their use. However, cases of irrational prescription or uncontrolled use of GCS are not uncommon, which significantly increases the risk of developing local and systemic side effects.
Description of a series of clinical cases. The article presents clinical observations of severe side effects of long-term self-treatment with systemic and topical corticosteroids that developed in patients aged 66 and 56 years. Long-term irrational topical use of betamethasone dipropionate by one of the patients and the use of 2.0 ml of corticosteroids for injection by another – a combination of the depot form (betamethasone sodium phosphate 2.63 mg) and the fast-acting form (betamethasone dipropionate 6.43 mg) – led to the formation of exogenous Cushing’s syndrome, infectious and other complications.
Conclusion. Violation of the rules for the use of GCS, as well as self-medication, lead to a high risk of developing both local and general side effects.
Негізгі сөздер
Толық мәтін
Авторлар туралы
О. Nemchaninova
Novosibirsk State Medical University
Email: obnemchaninova@mail.ru
ORCID iD: 0000-0002-5961-6980
Ресей, Novosibirsk
Tatyana Reshetnikova
Novosibirsk State Medical University
Хат алмасуға жауапты Автор.
Email: obnemchaninova@mail.ru
ORCID iD: 0000-0002-6156-0875
Dr. Sci. (Med.), Professor, Department of Dermatovenereology and Cosmetology
Ресей, NovosibirskO. Pozdnyakova
Novosibirsk State Medical University
Email: obnemchaninova@mail.ru
ORCID iD: 0000-0003-1389-1001
Ресей, Novosibirsk
R. German
Novosibirsk State Medical University
Email: obnemchaninova@mail.ru
ORCID iD: 0009-0008-0462-8109
Ресей, Novosibirsk
Әдебиет тізімі
- Sulzberger M.B., Witten V.H. Effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19:101–2. doi: 10.1038/jid.1952.72.
- Клинические рекомендации «Пузырчатка», 2020. URL: https://www.rodv.ru/upload/iblock/eac/eacb3e5d68c5dde0145d239 c1260ac30.docx
- Schafer-Korting M., Kleuser B., Ahmed M., et al. Glucocorticoids for human skin: New aspects of the mechanism of action. Skin Pharmacol Physiol. 2005;18:1032–14. doi: 10.1159/000084907.
- Goa K.L. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review. Drugs. 1988;36(5):51–61. doi: 10.2165/00003495-198800365-00011.
- Katzung B.G., Trevor A.J., Masters S.B. Basic and Clinical Pharmacology. 11th ed. New York: McGraw-Hill, 2009. Р. 681–99.
- Зайчик А.Ш., Чурилов Л.П. Общая патофизиология (с основами иммунопатологии) Изд. 4-е. СПб., 2008. [Zaichik A.S., Churilov L.P. General pathophysiology (with the basics of immunopathology) 4th edition. SPb., 2008 (In Russ.)].
- Литвинов В.А. Акантолитическая пузырчатка: осложнения после применения терапии глюкокортикостероидами. Дерматовенерология. Косметология. Сексопатология. 2012;1(4): 235–37. [Litvinov V.A. Acantholytic pemphigus: complications after glucocorticosteroid therapy. Dermatovenerologiya. Kosmetologiya. Seksopatologiya. 2012;1(4):235–37. (In Russ.)].
- Joe E.K. Cushing syndrome secondary to topical glucocorticoids. Dermatol On-line J. 2003;9(4):16. doi: 10.5070/D33ns8x0t5.
- Потекаев Н.С., Львов А.Н., Фадеев В.В., Самойленко В.В. Тяжелые системные побочные эффекты топической стероидной терапии псориаза. Клиническая дерматология и венерология. 2013;11(1):31–7. [Potekaev N.S., Lvov A.N., Fadeev V.V., Samoilenko V.V. Severe systemic side effects of topical steroid therapy for psoriasis. Klinicheskaya dermatologiya i venerologiya. 2013;11(1):31–7. (In Russ.)].
- Борисова Е.О. Побочные эффекты системной глюкокортикостероидной терапии. Атмосфера. Пульмонология и аллергология. 2004;3:14–8. [Borisova E.O. Side effects of systemic glucocorticosteroid therapy. Atmosfera. Pul’monologiya i allergologiya. 2004;3:14–8. (In Russ.)].
- Abma E.M., Blanken R., De Heide L.J. Cushing’s syndrome caused by topical steroid therapy for psoriasis. Neth J Med. 2002;60(3):148–50.
- Ohnishi T., Suzuki T., Watanabe S., Takahashi H. Erythrodermic psoriasis associated with hyperuricemia and iatrogenic Cushing‘s syndrome due to topical corticosteroid therapy. Int J Dermatol. 1996;35(5):379–80. doi: 10.1111/j.1365-4362.1996.tb03647.x.
- Kuikel S., Aryal S., Basnyat R.S., Rimal S. Cushing Syndrome in a Pediatric Patient with Topical Steroid Overuse. Case Rep Endocrinol. 2022;2022:8487737. doi: 10.1155/2022/8487737.
Қосымша файлдар
